Related Experiment Video
Updated: Jul 10, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
A Multi-Omics Approach Revealed Common Dysregulated Pathways in Type One and Type Two Endometrial Cancers
Valeria Capaci1, Lorenzo Monasta1, Michelangelo Aloisio1
1Institute for Maternal and Child Health, IRCCS Institute for Maternal and Child Health-IRCCS Burlo Garofolo, 34137 Trieste, Italy.
Abstract:
Endometrial cancer (EC) is the most frequent gynecologic cancer in postmenopausal women. Pathogenetic mechanisms that are related to the onset and progression of the disease are largely still unknown. A multi-omics strategy can help identify altered pathways that could be targeted for improving therapeutical approaches. In this study we used a multi-omics approach on four EC cell lines for the identification of common dysregulated pathways in type 1 and 2 ECs. We analyzed proteomics and metabolomics of AN3CA, HEC1A, KLE and ISHIKAWA cell lines by mass spectrometry. The bioinformatic analysis identified 22 common pathways that are in common with both types of EC. In addition, we identified five proteins and 13 metabolites common to both types of EC. Western blotting analysis on 10 patients with type 1 and type 2 EC and 10 endometria samples confirmed the altered abundance of NPEPPS. Our multi-omics analysis identified dysregulated proteins and metabolites involved in EC tumor growth. Further studies are needed to understand the role of these molecules in EC. Our data can shed light on common pathways to better understand the mechanisms involved in the development and growth of EC, especially for the development of new therapies.
Insights
This study used multi-omics to find common pathways in endometrial cancer (EC). Researchers identified key proteins and metabolites, offering new therapeutic targets for this common gynecologic cancer.
Area of Science:
- Gynecologic Oncology
- Molecular Biology
- Biochemistry
Background:
- Endometrial cancer (EC) is the most common gynecologic malignancy in postmenopausal women.
- The underlying pathogenetic mechanisms of EC development and progression remain largely unknown.
- Targeting dysregulated pathways presents a promising strategy for improving EC therapeutics.
Purpose of the Study:
- To employ a multi-omics approach to identify common dysregulated pathways in type 1 and type 2 endometrial cancer.
- To discover shared molecular alterations that could serve as therapeutic targets for EC.
- To enhance the understanding of EC pathogenesis through integrated proteomic and metabolomic analyses.
Main Methods:
- Utilized a multi-omics strategy, including proteomics and metabolomics, on four EC cell lines (AN3CA, HEC1A, KLE, ISHIKAWA).
- Analyzed protein and metabolite profiles using mass spectrometry.
- Validated findings through Western blotting on patient samples and healthy endometria.
Main Results:
- Identified 22 common dysregulated pathways shared by both type 1 and type 2 EC.
- Discovered five common proteins and 13 common metabolites across both EC types.
- Confirmed altered abundance of NPEPPS in EC patients compared to controls.
Conclusions:
- The multi-omics analysis successfully identified dysregulated proteins and metabolites implicated in EC tumor growth.
- These findings provide insights into common molecular pathways crucial for EC development and progression.
- Further research into the identified molecules may lead to novel therapeutic strategies for endometrial cancer.
